QIAGEN N.V. Announces Business Combination with EQT Private Equity and Suspends 2026 Outlook

QIAGEN N.V. has entered into a Business Combination Agreement with EQT Private Equity. The agreement allows EQT, along with co-investors Luxinva S.A. and CPP Investment Board, to make a public tender offer for all QIAGEN shares at EUR 46.50 each. This values the company at approximately EUR 10.8 billion, representing significant premiums to its share prices in July.

The acquisition proposal followed extensive reviews and was unanimously approved by QIAGEN's Supervisory and Managing Boards. The Boards encourage shareholders to accept the offer during an Extraordinary General Meeting. The takeover aims to enhance QIAGEN’s growth potential under private ownership.

Furthermore, QIAGEN's third-quarter 2026 results were reported with net sales of USD 548 million. The company also announced a suspension of its full-year 2026 outlook pending the transaction's closure.